Microglial activation, tau and amyloid deposition in TREM2 p.R47H carriers and mild cognitive impairment patients: a multi-modal/multi-tracer PET/MRI imaging study with influenza vaccine immune challenge

Table 3 FreeSurfer-derived regions of interest volumes (cm³) were compared based on study group

Region	Imaging controls (n = 8)	MCI (n = 8)	TREM2 p.R47H (n = 8)
TBV (mean ± SD)	1244 ± 94.2	999.6 ± 107.6	1029 ± 47.0^a
Frontal (mean ± SD)	175.0 ± 18.2	151.2 ± 14.2	156.5 ± 11.5
Temporal (mean ± SD)	118.1 ± 12.1	102.8 ± 12.2	99.56 ± 7.20
Parietal (mean ± SD)	114.3 ± 15.7	98.88 ± 10.3	104.1 ± 4.32
Hippocampus (mean ± SD)	9.191 ± 0.724	7.258 ± 0.740	7.826 ± 0.570
Putamen (mean ± SD)	10.77 ± 0.563	8.871 ± 1.33	9.467 ± 0.993
Caudate (mean ± SD)	7.526 ± 0.619	6.531 ± 0.944	6.438 ± 0.519^a
White matter (mean ± SD)	559.5 ± 47.7	410.3 ± 63.4	424.8 ± 23.5^a

Age, sex and intracranial volume included as covariates for statistical comparison
MCI mild cognitive impairment, SD standard deviation, TBV total brain volume
^aTREM2 p.R47H carrier significant versus controls; P < 0.05

ISSN: 1742-2094